Home LiteratureArticle Details
PMID: 3063494 Published · ppublish English Journal Article Review

Enoxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Drugs ·Vol. 36 ·No. 1 ·1988-07-00 ·Pages 32-66

Henwood JM, Monk JP

Abstract

Enoxacin is a new addition to the class of 4-quinolone antibacterial drugs. It has a broad spectrum of in vitro antibacterial activity, and is particularly potent against Gram-negative organisms and staphylococci. The pharmacokinetic profile of enoxacin is similar to that of ofloxacin, achieving higher plasma and tissue concentrations and possessing a longer half-life than norfloxacin or ciprofloxacin. In comparative studies, clinical and/or bacteriological efficacy was comparable or (in studies which statistically analysed the results) not significantly different between enoxacin and amoxycillin in acute cystitis, acute Gram-negative exacerbations of chronic bronchitis and acute or chronic otitis media, between enoxacin and cephalexin in skin, skin structure and soft tissue infections, between enoxacin and trimethoprim in acute cystitis, between enoxacin and co-trimoxazole in complicated urinary tract infection and between enoxacin and pipemidic acid in suppurative otitis media. Significantly (p less than 0.01) more clinical and/or bacteriological cures were effected by enoxacin than pipemidic acid in acute cystitis and complicated urinary tract infection. In uncomplicated gonococcal infections single oral doses of enoxacin were effective in over 90% of patients. Enoxacin is a well-tolerated, orally active broad spectrum antibacterial drug which should prove a worthwhile alternative to currently available antibacterial therapy.

MeSH Terms
Anti-Infective Agents/pharmacokinetics,pharmacology,therapeutic use Anti-Infective Agents, Urinary/pharmacokinetics,pharmacology,therapeutic use Enoxacin/pharmacokinetics,pharmacology,therapeutic use Humans Urinary Tract Infections/drug therapy
Chemicals
Anti-Infective Agents Anti-Infective Agents, Urinary Enoxacin
Authors & Affiliations
2 authors, click to expand affiliations / ORCID
Henwood J M
ADIS Drug Information Services, Manchester, England.
Monk J P
References (125)
125 references, click to expand
  1. In-vitro activity of enoxacin (CL-919), a new quinoline derivative, compared with that of other antimicrobial agents.
    J Antimicrob Chemother. 1984 Mar;13(3):237-44 PMID: 6586712
  2. Comparative evaluation of enoxacin, ofloxacin, ampicillin, and chloramphenicol for treatment of experimental Haemophilus influenzae pneumonia.
    Antimicrob Agents Chemother. 1987 Mar;31(3):417-20 PMID: 3495234
  3. Cross-resistance among cinoxacin, ciprofloxacin, DJ-6783, enoxacin, nalidixic acid, norfloxacin, and oxolinic acid after in vitro selection of resistant populations.
    Antimicrob Agents Chemother. 1984 Jun;25(6):775-7 PMID: 6234858
  4. Penetration of enoxacin into bronchial secretions.
    Antimicrob Agents Chemother. 1987 May;31(5):748-51 PMID: 3475036
  5. Inhibition of R-plasmid transfer in Escherichia coli by 4-quinolones.
    Antimicrob Agents Chemother. 1987 Apr;31(4):531-4 PMID: 3300531
  6. Treatment of uncomplicated urogenital gonorrhoea in women with a single dose of enoxacin.
    Eur J Clin Microbiol. 1986 Aug;5(4):395-8 PMID: 3093221
  7. Enoxacin in the treatment of sexually transmitted diseases.
    J Antimicrob Chemother. 1988 Feb;21 Suppl B:119-24 PMID: 3283097
  8. A double blind study comparing two dosages of enoxacin for the treatment of uncomplicated urogenital gonorrhoea.
    J Antimicrob Chemother. 1984 Sep;14 Suppl C:91-4 PMID: 6438048
  9. The effect of renal impairment and haemodialysis on single dose pharmacokinetics of oral enoxacin.
    J Antimicrob Chemother. 1988 Feb;21 Suppl B:87-95 PMID: 3162906
  10. In vitro and in vivo antibacterial activity of AT-2266.
    Antimicrob Agents Chemother. 1983 Jul;24(1):78-84 PMID: 6226242
  11. Quinolone/ureidopenicillin cross-resistance.
    Lancet. 1987 Oct 17;2(8564):907 PMID: 2889094
  12. [Diffusion, in the bronchial mucus, of enoxacin administered by oral route in man].
    Pathol Biol (Paris). 1987 Jun;35(5 Pt 2):781-4 PMID: 3309815
  13. In vitro activity of CI-919 (AT-2266), an oral antipseudomonal compound.
    Antimicrob Agents Chemother. 1983 May;23(5):658-63 PMID: 6223577
  14. Nalidixic-acid-resistant Shigella dysenteriae I.
    Lancet. 1985 Mar 30;1(8431):763 PMID: 2858035
  15. Enoxacin concentration in human prostatic tissue after oral administration.
    J Antimicrob Chemother. 1986 Jan;17(1):123 PMID: 2419299
  16. Enoxacin treatment of urinary tract infections.
    J Antimicrob Chemother. 1985 Jun;15(6):759-63 PMID: 3861605
  17. The comparative pharmacokinetics and tissue penetration of four quinolones including intravenously administered enoxacin.
    Infection. 1986;14 Suppl 3:S196-202 PMID: 3463542
  18. Mode of incomplete cross-resistance among pipemidic, piromidic, and nalidixic acids.
    Antimicrob Agents Chemother. 1978 Aug;14(2):240-5 PMID: 358918
  19. Treatment of experimental Pseudomonas corneal ulcers with enoxacin, a quinolone antibiotic.
    Arch Ophthalmol. 1986 Aug;104(8):1230-2 PMID: 3461752
  20. Influence of medium and method on the in vitro susceptibility of Pseudomonas aeruginosa and other bacteria to ciprofloxacin and enoxacin.
    Antimicrob Agents Chemother. 1986 May;29(5):927-9 PMID: 2942102
  21. Incomplete cross-resistance of nalidixic and pipemidic acid-resistant variants of Serratia marcescens against ciprofloxacin, enoxacin, and norfloxacin.
    Chemotherapy. 1985;31(1):34-9 PMID: 3156026
  22. Quinolones: pharmacology.
    Pharm Weekbl Sci. 1986 Feb 21;8(1):22-5 PMID: 3008075
  23. Cross-resistance of nalidixic acid resistant Enterobacteriaceae to new quinolones and other antimicrobials.
    Eur J Clin Microbiol. 1986 Aug;5(4):411-5 PMID: 3758052
  24. Influence of various antibiotics on phagocytosis of Staphylococcus aureus by human polymorphonuclear leucocytes.
    J Antimicrob Chemother. 1987 Sep;20(3):399-404 PMID: 3680077
  25. Comparative in-vitro activity of five fluoroquinolones against mycobacteria.
    J Antimicrob Chemother. 1987 May;19(5):605-9 PMID: 3112094
  26. [In vitro antimicrobial activity of CI-919 against gram-negative bacilli and Staphylococcus aureus isolated from various pathologies].
    Rev Med Chil. 1985 Feb;113(2):94-102 PMID: 3866270
  27. Comparative in vitro activities of ciprofloxacin, enoxacin, norfloxacin, ofloxacin and pefloxacin against Bacteroides fragilis and Clostridium difficile.
    Scand J Infect Dis. 1986;18(2):149-51 PMID: 2939556
  28. An open study of the safety and efficacy of enoxacin in complicated urinary tract infections.
    J Antimicrob Chemother. 1988 Feb;21 Suppl B:97-103 PMID: 3129393
  29. In vitro susceptibility of Campylobacter jejuni to 27 antimicrobial agents and various combinations of beta-lactams with clavulanic acid or sulbactam.
    Antimicrob Agents Chemother. 1985 Jul;28(1):37-40 PMID: 2994557
  30. Elimination of plasmids from Enterobacteriaceae by 4-quinolone derivatives.
    J Antimicrob Chemother. 1986 Dec;18(6):667-74 PMID: 3029010
  31. In-vitro activity of newer quinolones against aerobic bacteria.
    J Antimicrob Chemother. 1986 Apr;17 Suppl B:29-39 PMID: 2940214
  32. In vitro comparison of A-56619, A-56620, amifloxacin, ciprofloxacin, enoxacin, norfloxacin, and ofloxacin against methicillin-resistant Staphylococcus aureus.
    Antimicrob Agents Chemother. 1986 Feb;29(2):325-6 PMID: 2940966
  33. Effect of food on enoxacin absorption.
    Antimicrob Agents Chemother. 1987 Apr;31(4):638-9 PMID: 3475034
  34. Enoxacin: in-vitro and animal evaluation as a parenteral and oral agent against hospital bacterial isolates.
    J Antimicrob Chemother. 1988 Feb;21 Suppl B:29-42 PMID: 3129392
  35. Urinary enoxacin concentration and excretion after a single dose.
    N Z Med J. 1985 Mar 13;98(774):159 PMID: 3856178
  36. Influence of various antibiotics on superoxide generation by normal human neutrophils.
    Arch Int Physiol Biochim. 1986 Dec;94(5):S23-8 PMID: 2440398
  37. Comparative antimicrobial activity of enoxacin, ciprofloxacin, amifloxacin, norfloxacin and ofloxacin against 177 bacterial isolates.
    J Antimicrob Chemother. 1986 May;17(5):623-8 PMID: 2941401
  38. The comparative in-vitro activity of twelve 4-quinolone antimicrobials against Haemophilus ducreyi.
    J Antimicrob Chemother. 1985 Aug;16(2):165-8 PMID: 3877717
  39. Comparative in vitro activities of ten antimicrobial agents against bacterial enteropathogens.
    Antimicrob Agents Chemother. 1983 Oct;24(4):509-13 PMID: 6651278
  40. Pharmacokinetics and sputum penetration of enoxacin after twice daily oral dosing for seven days.
    J Antimicrob Chemother. 1988 Feb;21 Suppl B:61-6 PMID: 3162903
  41. Comparative double-blind study of 200- and 400-mg enoxacin given orally in the treatment of acute uncomplicated urethral gonorrhea in males.
    Antimicrob Agents Chemother. 1987 Apr;31(4):535-8 PMID: 3111354
  42. 4-Quinolone drugs affect cell cycle progression and function of human lymphocytes in vitro.
    Antimicrob Agents Chemother. 1987 May;31(5):768-73 PMID: 3606076
  43. Enoxacin in lower respiratory tract infections.
    J Antimicrob Chemother. 1986 Dec;18(6):719-27 PMID: 3469179
  44. The comparative in-vitro activity of norfloxacin, ciprofloxacin, enoxacin and nalidixic acid against 423 strains of gram-negative rods and staphylococci isolated from infected hospitalised patients.
    J Antimicrob Chemother. 1986 Jan;17(1):63-7 PMID: 2936708
  45. Enoxacin compared with cefoperazone for the treatment of experimental Enterobacter aerogenes endocarditis.
    Antimicrob Agents Chemother. 1985 May;27(5):708-11 PMID: 3860186
  46. Enoxacin distribution in human tissues after multiple oral administration.
    J Antimicrob Chemother. 1988 Feb;21 Suppl B:57-60 PMID: 3162902
  47. Comparative effects of enoxacin and norfloxacin on human colonic microflora.
    Antimicrob Agents Chemother. 1987 Nov;31(11):1846-8 PMID: 3481249
  48. Enoxacin treatment of urinary tract infections in elderly patients.
    J Antimicrob Chemother. 1988 Feb;21 Suppl B:105-11 PMID: 3162900
  49. [Comparative studies of enoxacin and amoxicillin for acute uncomplicated cystitis in women].
    Infection. 1986;14 Suppl 3:S209-10 PMID: 3463544
  50. Enoxacin-warfarin interaction: pharmacokinetic and stereochemical aspects.
    Clin Pharmacol Ther. 1987 Jul;42(1):33-41 PMID: 3474093
  51. Enoxacin-induced alteration of susceptibility of pneumococci and Pseudomonas to phagocytosis by human polymorphonuclear leukocytes.
    J Antimicrob Chemother. 1984 Sep;14 Suppl C:19-31 PMID: 6438047
  52. Comparative evaluation of recently developed quinolone compounds--with a note on the frequency of resistant mutants.
    Chemotherapy. 1985;31(1):19-28 PMID: 3156025
  53. Comparative in vitro activity of seven quinolones against 100 clinical isolates of Clostridium difficile.
    Antimicrob Agents Chemother. 1986 Feb;29(2):374-5 PMID: 2940968
  54. In vitro activity of enoxacin, a quinolone carboxylic acid, compared with those of norfloxacin, new beta-lactams, aminoglycosides, and trimethoprim.
    Antimicrob Agents Chemother. 1983 Nov;24(5):754-63 PMID: 6229216
  55. Pharmacokinetics of AT-2266 administered orally to mice, rats, dogs, and monkeys.
    Antimicrob Agents Chemother. 1983 Jul;24(1):54-60 PMID: 6226241
  56. In-vitro activity of pefloxacin compared to enoxacin, norfloxacin, gentamicin and new beta-lactams.
    J Antimicrob Chemother. 1985 Jan;15(1):39-44 PMID: 3156112
  57. In-vitro activity of six fluorinated quinolones against Mycobacterium tuberculosis.
    J Antimicrob Chemother. 1987 May;19(5):611-5 PMID: 3112095
  58. The clinical pharmacokinetics and tolerance of enoxacin in healthy volunteers.
    J Antimicrob Chemother. 1984 Sep;14 Suppl C:63-9 PMID: 6389476
  59. Enoxacin for the treatment of urinary tract infection.
    N Z Med J. 1985 Apr 24;98(777):286-8 PMID: 3857511
  60. Comparative in vitro activities of pefloxacin, ofloxacin, enoxacin and ciprofloxacin against 256 clinical isolates.
    Acta Pathol Microbiol Immunol Scand B. 1987 Apr;95(2):141-6 PMID: 3473910
  61. Efficacy of enoxacin in the treatment of bacterial infections of the skin with regards to photosensitization.
    Infection. 1986;14 Suppl 3:S213-6 PMID: 3463546
  62. The influence of quinolone derivatives on theophylline clearance.
    Br J Clin Pharmacol. 1986 Dec;22(6):677-83 PMID: 3567014
  63. Ofloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.
    Drugs. 1987 Apr;33(4):346-91 PMID: 3297617
  64. In-vitro activity of enoxacin against aminoglycoside-resistant gram-negative bacilli and other clinical isolates.
    J Antimicrob Chemother. 1984 Sep;14 Suppl C:1-6 PMID: 6438046
  65. In-vitro activity of enoxacin against gonococcal isolates in comparison with that of five other antibiotics.
    J Antimicrob Chemother. 1988 Feb;21 Suppl B:43-8 PMID: 2966141
  66. Serum and sputum concentrations of enoxacin after single oral dosing in a clinical and bacteriological study.
    J Antimicrob Chemother. 1984 Sep;14 Suppl C:83-9 PMID: 6594325
  67. Comparative in vitro activities of selected antimicrobial agents against Aeromonas species and Plesiomonas shigelloides.
    Antimicrob Agents Chemother. 1985 Apr;27(4):643-5 PMID: 4004196
  68. High-performance liquid chromatography and preliminary pharmacokinetics of enoxacin and its 4-oxo metabolite in human plasma, urine and saliva.
    J Chromatogr. 1985 Oct 11;343(2):449-54 PMID: 3864785
  69. Elimination of enoxacin in renal disease.
    Clin Pharmacol Ther. 1987 Apr;41(4):434-8 PMID: 3470166
  70. Antimicrobial activity of ciprofloxacin against Pseudomonas aeruginosa, Escherichia coli, and Staphylococcus aureus determined by the killing curve method: antibiotic comparisons and synergistic interactions.
    Antimicrob Agents Chemother. 1985 Aug;28(2):331-42 PMID: 2939797
  71. Gyrase-inhibitors impair caffeine elimination in man.
    Methods Find Exp Clin Pharmacol. 1987 Mar;9(3):193-8 PMID: 3037212
  72. Oral enoxacin used to cure spinal osteomyelitis due to aminoglycoside-resistant Pseudomonas aeruginosa.
    N Z Med J. 1985 Jun 26;98(781):508 PMID: 3859782
  73. Convulsions related to enoxacin.
    Lancet. 1985 Jul 20;2(8447):161 PMID: 2862357
  74. Pharmacokinetics of intravenous and oral enoxacin in healthy volunteers.
    J Antimicrob Chemother. 1988 Feb;21 Suppl B:49-56 PMID: 3162901
  75. Double blind, randomised trial comparing single dose enoxacin and trimethoprim for treatment of bacterial cystitis.
    N Z Med J. 1987 Oct 14;100(833):618-9 PMID: 3330593
  76. Enoxacin decreases the clearance of theophylline in man.
    Br J Clin Pharmacol. 1985 Dec;20(6):583-8 PMID: 3867394
  77. Pharmacokinetics of enoxacin and its penetration into bronchial secretions and lung tissue.
    J Antimicrob Chemother. 1988 Feb;21 Suppl B:67-77 PMID: 3162904
  78. In vitro activity of enoxacin compared with norfloxacin and amikacin.
    Eur J Clin Microbiol. 1985 Feb;4(1):55-8 PMID: 3157568
  79. Antibacterial activity of enoxacin: comparison with aminoglycosides, beta-lactams and other antimicrobial agents.
    J Antimicrob Chemother. 1986 Mar;17(3):297-302 PMID: 3457785
  80. Enoxacin: worldwide in-vitro activity against 22451 clinical isolates.
    J Antimicrob Chemother. 1984 Sep;14 Suppl C:47-55 PMID: 6594322
  81. Elimination of plasmids by enoxacin and ofloxacin at near inhibitory concentrations.
    J Antimicrob Chemother. 1986 Nov;18(5):575-83 PMID: 3542924
  82. Differentiation of Mycobacterium gordonae from Mycobacterium scrofulaceum and Mycobacterium szulgai by susceptibility to enoxacin (antimycobacterial activity of enoxacin).
    Microbiol Immunol. 1986;30(9):931-3 PMID: 3467156
  83. Intravenous enoxacin for the treatment of acute pyelonephritis: pharmacokinetic and clinical study.
    Br J Clin Pharmacol. 1988 Feb;25(2):223-8 PMID: 3162809
  84. Clinical pharmacokinetics of the newer antibacterial 4-quinolones.
    Clin Pharmacokinet. 1988 Feb;14(2):96-121 PMID: 3282749
  85. A comparison of enoxacin and co-trimoxazole in the treatment of patients with complicated urinary tract infections.
    J Antimicrob Chemother. 1988 Feb;21 Suppl B:113-8 PMID: 3258862
  86. In vitro activities of enoxacin, ticarcillin plus clavulanic acid, aztreonam, piperacillin, and imipenem and comparison with commonly used antimicrobial agents.
    Antimicrob Agents Chemother. 1985 Aug;28(2):259-64 PMID: 3869433
  87. Enoxacin in the treatment of lower respiratory tract infections.
    J Antimicrob Chemother. 1988 Feb;21 Suppl B:125-9 PMID: 3258863
  88. In-vitro antimicrobial activity of enoxacin in combination with eight other antibiotics against Pseudomonas aeruginosa, Enterobacteriaceae and Staphylococcus aureus.
    J Antimicrob Chemother. 1987 Jan;19(1):45-8 PMID: 3104277
  89. Comparison of difloxacin, enoxacin, and cefoperazone for treatment of experimental Enterobacter aerogenes endocarditis.
    Antimicrob Agents Chemother. 1987 Mar;31(3):458-60 PMID: 3472489
  90. Enoxacin in the treatment of complicated urinary tract infections.
    Aust N Z J Med. 1987 Feb;17(1):81-2 PMID: 3304243
  91. Antibacterial activities of ciprofloxacin, norfloxacin, oxolinic acid, cinoxacin, and nalidixic acid.
    Antimicrob Agents Chemother. 1984 May;25(5):633-7 PMID: 6233935
  92. The effect of age on the pharmacokinetics of enoxacin.
    Eur J Clin Pharmacol. 1987;33(1):101-4 PMID: 3480221
  93. Treatment of bacillary dysentery: a comparison between enoxacin and nalidixic acid.
    J Antimicrob Chemother. 1987 May;19(5):695-8 PMID: 3301783
  94. Pharmacokinetics and tolerance of enoxacin in healthy volunteers administered at a dosage of 400 mg twice daily for 14 days.
    J Antimicrob Chemother. 1984 Sep;14 Suppl C:71-4 PMID: 6389477
  95. The activity of enoxacin against clinical bacterial isolates in comparison with that of five other agents, and factors affecting that activity.
    J Antimicrob Chemother. 1984 Sep;14 Suppl C:7-17 PMID: 6594324
  96. The pharmacokinetics and tissue penetration of enoxacin and norfloxacin.
    J Antimicrob Chemother. 1984 Sep;14 Suppl C:75-81 PMID: 6238932
  97. Enoxacin compared with vancomycin for the treatment of experimental methicillin-resistant Staphylococcus aureus endocarditis.
    Antimicrob Agents Chemother. 1986 Mar;29(3):461-3 PMID: 3459391
  98. In vitro activities of enoxacin and 17 other antimicrobial agents against multiply resistant, gram-negative bacteria.
    Antimicrob Agents Chemother. 1984 Jul;26(1):97-100 PMID: 6591853
  99. Nalidixic acid-resistant mutations of the gyrB gene of Escherichia coli.
    Mol Gen Genet. 1986 Sep;204(3):367-73 PMID: 3020376
  100. The quinolones in chronic bronchitis.
    Pharm Weekbl Sci. 1986 Feb 21;8(1):53-9 PMID: 3960693
  101. Penetration of enoxacin into human bronchial mucosa.
    Am Rev Respir Dis. 1986 Dec;134(6):1209-12 PMID: 3466562
  102. Comparative bactericidal activity of cefixime, carumonam, enoxacin and roxithromycin with those of other antibiotics against resistant Haemophilus influenzae including beta-lactam tolerant strains.
    J Antimicrob Chemother. 1987 Nov;20(5):663-9 PMID: 3501422
  103. Interaction of gentamicin, dibekacin, netilmicin and amikacin with various penicillins, cephalosporins, minocycline and new fluoro-quinolones against Enterobacteriaceae and Pseudomonas aeruginosa.
    J Antimicrob Chemother. 1985 Nov;16(5):581-7 PMID: 3935637
  104. An evaluation of pelvic tissue concentrations after oral administration of enoxacin.
    J Antimicrob Chemother. 1988 Feb;21 Suppl B:79-85 PMID: 3162905
  105. Comparative evaluation of ciprofloxacin, enoxacin, and ofloxacin in experimental Pseudomonas aeruginosa pneumonia.
    Antimicrob Agents Chemother. 1986 Mar;29(3):395-9 PMID: 2940970
  106. Diffusion of enoxacin into the cerebrospinal fluid in dogs with healthy meninges and with experimental meningitis.
    J Antimicrob Chemother. 1984 Sep;14 Suppl C:57-62 PMID: 6594323
  107. The comparative activity of pefloxacin, enoxacin, ciprofloxacin and 13 other antimicrobial agents against enteropathogenic microorganisms.
    Infection. 1986 Nov-Dec;14(6):294-8 PMID: 3546145
  108. In vitro activities of five new quinolones against 88 genital and neonatal Haemophilus isolates.
    Antimicrob Agents Chemother. 1988 Jan;32(1):147-9 PMID: 3258143
  109. Effects of ethylenediaminetetraacetic acid and gentamicin on the antibacterial activity of pyridone carboxylic acid derivatives against gram-negative bacilli.
    J Antimicrob Chemother. 1986 Mar;17(3):327-32 PMID: 3084441
  110. [Results of treatment of bacterial inflammation of the skin with enoxacin].
    Infection. 1986;14 Suppl 3:S217-8 PMID: 3531029
  111. Enoxacin in the treatment of bronchopulmonary infections.
    Eur J Clin Microbiol. 1985 Oct;4(5):512-3 PMID: 3864640
  112. Comparative in vitro studies with 4-quinolone antimicrobials.
    Drugs Exp Clin Res. 1985;11(5):317-29 PMID: 2941259
  113. In vitro activity, pharmacokinetics, clinical safety and therapeutic efficacy of enoxacin in the treatment of patients with complicated urinary tract infections.
    Infection. 1986;14 Suppl 3:S203-8 PMID: 3463543
  114. Clinical and pharmacokinetic studies on enoxacin in ear, nose and throat infections.
    Infection. 1986;14 Suppl 3:S211-2 PMID: 3463545
  115. Activities of new quinoline derivatives against genital pathogens.
    Antimicrob Agents Chemother. 1985 Jan;27(1):76-8 PMID: 3920959
  116. Comparative in vitro activities of enoxacin (CI-919, AT-2266) and eleven antipseudomonal agents against aminoglycoside-susceptible and -resistant Pseudomonas aeruginosa strains.
    Antimicrob Agents Chemother. 1984 Sep;26(3):417-8 PMID: 6439116
  117. In vitro antibacterial properties of AT-2266, a new pyridonecarboxylic acid.
    Antimicrob Agents Chemother. 1983 May;23(5):641-8 PMID: 6575721
  118. In-vitro activity of enoxacin, ofloxacin, norfloxacin and nalidixic acid.
    J Antimicrob Chemother. 1984 Sep;14 Suppl C:33-8 PMID: 6238931
  119. Treatment of chancroid with enoxacin.
    Acta Derm Venereol. 1985;65(5):455-7 PMID: 2416179
  120. Comparative in-vitro activity of enoxacin against penicillinase- and non-penicillinase-producing Neisseria gonorrhoeae.
    Sex Transm Dis. 1987 Apr-Jun;14(2):111-2 PMID: 3112966
  121. Enoxacin in acute exacerbations of chronic bronchitis: a comparison with amoxycillin.
    J Antimicrob Chemother. 1988 Feb;21 Suppl B:131-6 PMID: 3129390
  122. Plasmid-mediated resistance to nalidixic acid in Shigella dysenteriae type 1.
    Lancet. 1987 Aug 22;2(8556):419-21 PMID: 2887725
  123. In-vitro sensitivity of legionellas, meningococci and mycoplasmas to ciprofloxacin and enoxacin.
    J Antimicrob Chemother. 1985 Jun;15(6):787-9 PMID: 3161857
  124. In vitro activity of CI-934 compared with ciprofloxacin, enoxacin, norfloxacin, and vancomycin.
    Diagn Microbiol Infect Dis. 1987 Apr;6(4):301-6 PMID: 3472704
  125. The in-vitro activities of enoxacin and ofloxacin compared with that of ciprofloxacin.
    J Antimicrob Chemother. 1985 May;15(5):551-8 PMID: 3159712
Article Info
Journal
Drugs
Abbr.
Drugs
ISSN
0012-6667
DOI
10.2165/00003495-198836010-00004
Published
1988-07-00
Pages
32-66
Language
English
Region
New Zealand
NLM ID
7600076
Subset
IM
External Links
PubMed source DOI: 10.2165/00003495-198836010-00004 View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2